|drug3996||no interventional study Wiki||1.00|
|drug3574||Ultrasound of the lower limbs Wiki||1.00|
|D003920||Diabetes Mellitus, NIH||0.20|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Patients with COVID-19 have special demographic characteristics including thromboembolic risk factors . The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit patient are not described. Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a prospective multicenter cohort study to collect the biological data necessary for its study.
Description: Measure of anti-Xa activity by chromogenic method.Measure: Measure of anti-Xa activity Time: Up to 1 month
Description: Hemorrhagic risk is composite of : Major haemorrhage as defined by the International Society on Thrombosis and Haemostasis (ISTH) definition clinically significant haemorrhageMeasure: Analysis of hemorrhagic risk Time: Up to 1 month
Description: Venous thromboembolic events is composite of: symptomatic or symptomatic proximal deep vein thrombosis asymptomatic or symptomatic pulmonary embolismMeasure: Venous thromboembolic events Time: Up to 1 month
Description: Rate of creatinine.Measure: Analysis individual patient characteristics by the biomarker of Kidney function Time: Up to 1 month
Description: Biomarker of inflammation is composite of C-reactive protein (CRP) and inflammatory cytokines.Measure: Analysis individual patient characteristics by the biomarker of inflammation Time: Up to 1 month
Description: Biomarker of coagulation is composite of fibrinogen and D-Dimers.Measure: Analysis individual patient characteristics by the biomarker of coagulation Time: Up to 1 month
Description: Analysis of weight, age, sex, height, presence of a high thrombotic risk factor (history of venous thrombotics, active cancer, invasive mechanical ventilation).Measure: Demographic characteristics Time: Up to 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports